Plasmaβ-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia
Identificadores
Identificadores
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2020Título da revista
Scientific Reports
Tipo de contido
Journal Article
DeCS
proteína ácida fibrilar de la glía | estudios de casos y controles | encéfalo | antipsicóticos | proteínas de neurofilamentos | humanos | escalas de valoración psiquiátrica | adulto | tubulina (proteína) | progresión de la enfermedad | esquizofreniaMeSH
Schizophrenia | Glial Fibrillary Acidic Protein | Neurofilament Proteins | Adult | Humans | Tubulin | Psychiatric Status Rating Scales | Brain | Case-Control Studies | Disease Progression | Antipsychotic AgentsResumo
Schizophrenia is a progressive disorder characterized by multiple psychotic relapses. After every relapse, patients may not fully recover, and this may lead to a progressive loss of functionality. Pharmacological treatment represents a key factor to minimize the biological, psychological and psychosocial impact of the disorder. The number of relapses and the duration of psychotic episodes induce a potential neuronal damage and subsequently, neurodegenerative processes. Thus, a comparative study was performed, including forty healthy controls and forty-two SZ patients divided into first-episode psychosis (FEP) and chronic SZ (CSZ) subgroups, where the CSZ sub group was subdivided by antipsychotic treatment. In order to measure the potential neuronal damage, plasma levels of beta-III tubulin, neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) were performed. The results revealed that the levels of these proteins were increased in the SZ group compared to the control group (P < 0.05). Moreover, multiple comparison analysis showed highly significant levels of beta-III tubulin (P = 0.0002), Nf-L (P = 0.0403) and GFAP (P < 0.015) in the subgroup of CSZ clozapine-treated. In conclusion, beta-III tubulin, Nf-L and GFAP proteins may be potential biomarkers of neurodegeneration and progression in SZ.